Description
Remestip (Terlipressin Acetate) Solution for Injections 0.1 mg/ml Ampoules 2 ml №5
Ingredients:
- Each 2 ml ampoule contains 0.1 mg of terlipressin acetate as the active ingredient.
Dosage:
- The recommended dosage of Remestip is determined by a healthcare professional and administered via intravenous injection.
Indications:
- Remestip is indicated for the treatment of hepatorenal syndrome, a serious complication of advanced liver disease.
Contraindications:
- Do not use Remestip in patients with known hypersensitivity to terlipressin or any other component of the formulation.
Directions:
- Remestip should be administered under the supervision of a healthcare provider experienced in the treatment of hepatorenal syndrome.
Scientific Evidence:
- Terlipressin, the active ingredient in Remestip, is a synthetic analog of vasopressin that acts as a systemic vasoconstrictor. It has been shown to improve renal function in patients with hepatorenal syndrome by increasing renal perfusion and reducing splanchnic blood flow.
- Clinical trials have demonstrated the efficacy of terlipressin in improving renal function and reducing mortality in patients with hepatorenal syndrome compared to placebo or other vasoconstrictor agents.
Additional Information:
- Remestip is a crucial treatment option for patients with hepatorenal syndrome, offering a targeted approach to improve renal function and outcomes in this high-risk population. It is essential to closely monitor patients receiving Remestip for any adverse reactions or changes in renal function.
- Consult the prescribing information and guidelines for detailed dosing recommendations and precautions when using Remestip in clinical practice.
